This document seeks to analyse how LDCs have utilized the 2016 extension to facilitate the production and access to HIV and other medicines for their populations; discuss what can be done to maximize the opportunities provided by the current extensions; describe the potential implications of LDCs having to implement the TRIPS Agreement with respect to pharmaceuticals and test data protection; fill the gaps in the understanding of the process for further extension of the transition period for pharmaceutical products; and provide recommendations on how LDCs should proceed to seek further extensions.
